We suggest that TT should not be started in patients with known familial or acquired thrombophilia, and recommend screening for familial and acquired thrombophilia, particularly FVL and the lupus anticoagulant, before starting TT, to identify men and women at high risk for VTE with an adverse risk-to-benefit ratio for TT. The gene discussed is F5; the disease is thrombophilia.